Hormonal
Metabolic syndrome (MetS) is independently associated with a higher risk of major cardiovascular events, cardiovascular mortality, and all-cause mortality, advancing the onset of these risks by approximately 3.2 years.
Having metabolic syndrome significantly increases your risk of heart attack, stroke, and early death, advancing the onset of these risks by over 3 years. However, managing individual components like high blood pressure, high triglycerides, or low HDL cholesterol is just as effective for risk reduction as treating the syndrome as a whole unit. Focus on controlling these specific metrics.
MetS was associated with higher risk of incidence of major cardiovascular event, cardiovascular and all-cause mortality... multivariable hazard ratio (95% confidence interval [CI]) among participants with MetS was 1.32 (1.01–1.74) with RAP (95% CI) of 3.23 years (0.03, 6.42) for major cardiovascular event... and 1.45 (1.17–1.80) with RAP of 3.24 years (1.21, 5.27) for all-cause mortality.
Why this rating
Large prospective cohort (n=3976), long follow-up (12.8 years), rigorous endpoint verification, but observational design limits causal inference.
Source
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort
María Jesús Guembe et al. · Cardiovascular Diabetology · 2020
DOI 10.1186/s12933-020-01166-6
More from this paper
- The number of metabolic syndrome traits (0-5) is positively associated with the incidence of major cardiovascular events, with each additional trait increasing the risk by 22%.Good
- Metabolic syndrome is NOT associated with a higher risk of myocardial infarction or stroke, although individual components like elevated blood pressure, reduced HDL, and elevated triglycerides are.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →